Jacobson Pharma Corporation Limited

SEHK:2633 Stock Report

Market Cap: HK$1.2b

Jacobson Pharma Past Earnings Performance

Past criteria checks 3/6

Jacobson Pharma's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2.7% per year. Jacobson Pharma's return on equity is 8.8%, and it has net margins of 12.7%.

Key information

-3.6%

Earnings growth rate

-2.8%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate2.7%
Return on equity8.8%
Net Margin12.7%
Last Earnings Update31 Mar 2024

Recent past performance updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Revenue & Expenses Breakdown

How Jacobson Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2633 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,4681863320
31 Dec 231,8112214230
30 Sep 231,9192174580
30 Jun 231,8522344430
31 Mar 231,2681752980
31 Dec 221,4892073600
30 Sep 221,4272033470
30 Jun 221,5111903730
31 Mar 221,5961783980
31 Dec 211,5481663990
30 Sep 211,5011544000
30 Jun 211,4731644040
31 Mar 211,4461744080
31 Dec 201,4781834050
30 Sep 201,5101914030
30 Jun 201,5412034020
31 Mar 201,5712144010
30 Sep 191,4192733650
30 Jun 191,4492593530
31 Mar 191,4782453410
31 Dec 181,6632353430
30 Sep 181,6222193350
30 Jun 181,5852113370
31 Mar 181,5492023390
31 Dec 171,4862023210
30 Sep 171,4242033030
30 Jun 171,3401913040
31 Mar 171,2561793040
31 Dec 161,1881423160
30 Sep 161,1411423220
30 Jun 161,1121443070
31 Mar 161,0841462930
31 Dec 151,0431452750
31 Mar 159481022460
31 Mar 149261722660

Quality Earnings: 2633 has high quality earnings.

Growing Profit Margin: 2633's current net profit margins (12.7%) are lower than last year (13.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2633's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: 2633's earnings growth over the past year (6.4%) exceeds its 5-year average (-3.6% per year).

Earnings vs Industry: 2633 earnings growth over the past year (6.4%) exceeded the Pharmaceuticals industry -5%.


Return on Equity

High ROE: 2633's Return on Equity (8.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.